Tous Actualités
Suivre
Abonner Oxygen Biotherapeutics Inc.

Oxygen Biotherapeutics Inc.

EANS-News: Oxygen Biotherapeutics Introduces Dermacyte® Oxygenating Eye Complex,an Oxygen-rich Serum to Reduce the Appearance of Fine Lines Around Eyes

Durham, NC (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
New Products/Biotechnology
DURHAM, NC, July 28, 2010 — Oxygen
Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today 
introduced its new, innovative skin care product, DERMACYTE® 
Oxygenating Eye Complex, a smooth, delicate eye serum specially 
designed to refresh, hydrate and restore the appearance of youth to 
the eye contour area. Beginning August 9th, retail orders can be 
placed on Oxygen Biotherapeutics´ secure website at 
www.BuyDermacyte.com.  Orders made by August 31st can receive free 
shipping in the U.S. and Canada by using the Code SHIPCOMPLEX10.
"The market to diminish the appearance of fine lines and wrinkles 
continues to grow as the last of the Baby Boomers nears 50 and 
Generations X & Y enter their 30´s and 40´s. We believe our 
oxygen-carrier skin care line is an excellent alternative to existing
products and procedures, and we intend to market and sell our 
products on-line, with an internal sales force and distributors, and 
through partners," said Maria Isabel Tamargo, Assistant Vice 
President of Marketing and Sales.
DERMACYTE Oxygenating Eye Complex is an enriched oxygen emollient 
developed by the makers of oxycyte technology (an oxygen carrier). It
is infused with avocado essence, soothing oat kernel, seed extract 
from the meadowfoam plant, Vitamin C, sunflower oil and calming high 
ash. These ingredients help improve hydration and prevent water loss,
while protecting your skin against environmental stress, flakiness, 
dryness, discoloration and puffiness in the eye area. It is 
hypoallergenic, paraben-free and reinforces skin firmness and tone 
around the eye area.  It is available in a 15 ml pump bottle that 
allows you to carefully dispense only the small amount needed for 
your eye area. The cost is $120.
Oxygen Benefits Your Skin Oxygen is essential for radiant, 
young-looking skin. It assists in the production of collagen and 
elastin, as well as with skin repair and regeneration.  As we age, 
the body´s ability to deliver oxygen to dermal tissue deteriorates. A
lack of oxygen at the cellular level can cause skin to age 
prematurely, increasing the appearance of fine lines and age spots, 
making skin look dry and dull. Oxygen therapies enhance the overall 
appearance and feel of your skin, leaving it smoother and 
healthier-looking.
About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is 
developing medical and cosmetic products that efficiently deliver 
oxygen to tissues in the body. The Company has developed a 
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and 
liquid ventilation product called Oxycyte® that is being formulated 
for both intravenous and topical delivery for conditions including 
but not limited to traumatic brain injury, decompression sickness and
topical wounds, as well as for personal skin care. More information 
is available at www.oxybiomed.com.
Caution Regarding Forward-Looking Statements This news release 
contains certain forward-looking statements by the company that 
involve risks and uncertainties and reflect the company's judgment as
of the date of this release. These statements include those referring
to the plans for the expansion of the Dermacyte product line and the 
timing of the introduction of those new products. Matters beyond the 
company´s control could lead to delays in the new product 
introductions and customer acceptance of these new products. 
Furthermore, there can be no assurance that such plans will lead to 
meaningful sales of Dermacyte or generate any revenue for the 
company. The company disclaims any intent or obligation to update 
these forward-looking statements beyond the date of this release. 
This caution is made under the safe harbor provisions of the Private 
Securities Litigation Reform Act of 1995.
end of announcement                               euro adhoc

Further inquiry note:

Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
2530 Meridian Pkwy, 3rd floor
Durham, NC 27713
Direct Telephone: +1 919 806 4405
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: 10728277
Index: SSIRT
Börsen: New York / Nasdaq
SIX Swiss Exchange / Main Standard

Plus de actualités: Oxygen Biotherapeutics Inc.
Plus de actualités: Oxygen Biotherapeutics Inc.